Stock UNCY UNICYCIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.13 USD +4.63% Intraday chart for Unicycive Therapeutics, Inc. +0.89% +30.23%
Apr. 04 Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target MT
Mar. 28 Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
AQ
Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target
MT
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
AQ
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
AQ
Unicycive Therapeutics, Inc. announced that it has received $50 million in funding
CI
Unicycive Announces $50 Million Private Placement
AQ
Unicycive Therapeutics, Inc. announced that it expects to receive $50 million in funding
CI
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
AQ
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia
MT
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
AQ
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate
CI
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?
PR
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
AQ
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
AQ
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
AQ
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
AQ
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
AQ
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
AQ
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. UNCY Stock
  4. News Unicycive Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW